PuREC Co., Ltd.

Basic information

Location (HQ)

Shimane, JP

Other location(s)

Tokyo, JP

Spinout from

Shimane University Medical School

Website

http://www.purec.jp/research_and_development/

CEO

Established in 

Shotai Kobayashi

2016

Business descriptions

PuREC is currently preparing the IND for hypophosphatasia (a rare bone-formation deficiency disease for new born babies) with our uniquely purified MSC (mesenchymal stem cell). Two other orthopedic disease are expected to file IND in a few years. We are confident that our specially purified MSC, called “REC”, can be applied also for other disease areas as well.
As our first-in-human trial is expected to start in 2021, we seek for license partners and investors to solidify furhter development; esipecially in Europe and U.S.

Business field

Shimane University Medical School

Keywords

MSC

stem cell therapy

hypophosphatasia

disc herination

TRL

6

Key literatures

https://drive.google.com/open?id=1C9bTppUARXj6jatmxXohB-oFH5EtXdoJ, https://drive.google.com/open?id=1tGRhM74jO9CSL52utU_HI6H7MWXD1roA

Company values

Number of filed patents

4

Patent IDs

​

Total patent value (USD)

No data

Business stage

Series A stage

Types of requested collaborations

R&D Collaboration, Investment, license partner

Ideal exit model

IPO in Japan

Introduction

PuREC is a spinout from Shimane University with patented technologies to produce purified MSC, or mesenchymal stem cells. PuREC's REC is coming from Rapidly Expanding Cells enabling the synthesis of 10^12 ordered pure cells within 12 weeks without requiring complicated methodologies such as gene-modification.

Licensing opportunity

(focusing on EU and US market)



Hypophosphatasia

Disc herniation

Joint disease

New applications including immunology diseases

Investment opportunity

Target $10M by 2022



Target other disease target POC

Create global business development team



Global investors outside Japan are also welcome